Fig 1: Comparison of gene and protein expression levels between SP and non-SP cells. (A) Western blots showing elevated expression of endosialin and stem cell surface proteins in SP cells. (B) Quantified results of reverse-transcription quantitative polymerase chain reaction analysis for expression of endosialin and other stemness genes in SP and non-SP cells. The elevated mRNA expression of endosialin, CD133, nestin, Oct-3/4A and Nanog are significantly higher in SP cells. The bar represents the standard deviation and **P<0.01 for non-SP vs. SP. SP, side population; ABC, adenosine triphosphate binding cassette; Oct, octamer-binding transcription factor.
Fig 2: Representative immunofluorescent staining images of sorted SP cells showing immunofluorescence positive to endosialin, CD133, Nanog and Oct3/4A (magnification, ×100). Nuclei were stained with DAPI. SP, side population; Oct, octamer-binding transcription factor.
Fig 3: Determination of clone formation efficiency of osteosarcoma SP cells. (A) The SP cells generate sarcospheres rapidly and significantly higher than non-SP cells. Values are expressed as the mean ± standard deviation. **P<0.01 for non-SP vs. SP. (B) Representative phase contrast images showing that SP cell-derived sarcospheres are bigger in size than those of non-SP cells. (C) Fluorescence microscopic images showing that SP cell-derived sarcospheres are CD133- and Oct3/4A-positive (magnification, ×100). SP, side population; Oct, octamer-binding transcription factor.
Fig 4: The roles of CD33+PD-L1+ cancer cells in the tumor resistant to adoptive macrophage therapy and hyperthermia adjuvant therapy.a Schematic illustration of tumor niche fostered by the CD133+PD-L1+ cancer cells resistant to the adoptive NPs-MΦ therapy. The mechanism involves 1) the inherent resistance of CD133+PD-L1+ cancer cells to the phagocytosis by the engineered macrophages; 2) the activation of CAFs to increase the stiffness of the ECM to prohibit the transferred macrophages and the effector CD8+ T cells from tumor trafficking; 3) the inhibition of the phagocytosis capacity of the adoptive macrophages as well as the tumor lysis ability of the CD8+ T cells through immunosuppressive factors. b Scheme for hyperthermia adjuvanticity to the adoptive macrophage transfer. Hyperthermia reverses the resistance of the CD133+PD-L1+ cancer cells to transferred macrophages by increasing the ‘eat me’ signal of CALR, cooperatively improving the therapeutic efficacy of the adoptive macrophage transfer.
Fig 5: Identification of CD133+PD-L1+ cancer cells with upregulated TGF-β signaling pathway following the NPs-MΦ transfer therapy.a Expression of PD-L1 in B16F10 cancer cells or NIH3T3 fibroblast cells in the co-culture with or without TGF-β. The expression of PD-L1 was normalized with the corresponding untreated B16F10 or NIH3T3 cells cultured alone. Two-way ANOVA with Sidak’s post-test (n = 4 biologically independent samples). b Expression of PD-L1 in the cancer cells and CAFs of mice following different treatments, normalized with the group of untreated day 8. Untreated day 16, the mice without treatment at day 16 reached a similar tumor size in volume ( ~ 500 mm3) to that of mice following the NPs-MΦ1 treatment at day 35. One-way ANOVA with Tukey’s post-test (n = 6 biologically independent samples for untreated day 8, n = 5 biologically independent samples for untreated day 16 or NPs-MΦ1 day 35). c Identification of CD133+PD-L1+ from the B16-GFP cancer cells of mice receiving the adoptive NPs-MΦ therapy. Tumors were collected from the NPs-MΦ1-treated mice at day 35. One-way ANOVA with Tukey’s post-test (n = 5 biologically independent mice). Right, representative dot plots of the flow cytometric analysis. d Flow cytometric analysis of TGF-β, IL-10 or VEGF-α production in GFP+CD133-PD-L1-, GFP+CD133+PD-L1-, GFP+CD133-PD-L1+ and GFP+CD133+PD-L1+ cancer cells of mice following the NPs-MΦ1 treatment at day 35, respectively. The expression of TGF-β, IL-10, or VEGF-α were normalized with the corresponding GFP+CD133+PD-L1- cancer cells. One-way ANOVA with Tukey’s post-test (n = 5 biologically independent samples for GFP+CD133-PD-L1- cancer cells, n = 4 biologically independent samples for GFP+CD133+PD-L1-, GFP+CD133-PD-L1+ or GFP+CD133+ PD-L1+ cancer cells). e Volcano plot indicating differentially expressed genes relevant to the TGF-β pathway. The x-axis indicates the log2-fold change for GFP+CD133+PD-L1+ versus GFP+CD133-PD-L1- cancer cells. The y-axis indicates the −1 × log10 of the Q value. Statistical significance was calculated using the two-sided Wald test for DESeq2 data. Source data are provided as a Source Data file.
Supplier Page from BioLegend for PE anti-mouse CD133